subscribeSubscribe
Vertex inks long-term access deal for CF meds in Englan

Vertex inks long-term access deal for CF meds in Englan
Fraiser Kansteiner FIERCE PHARMA
22 Jun 2024
Share Share
Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis

Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis
BUSINESSWIRE
23 Feb 2024
Share Share
Vertex`s sales of Trikafta hit $8.9B thanks to label expansion

Vertex`s sales of Trikafta hit $8.9B thanks to label expansion
FIERCE PHARMA
06 Feb 2024
Share Share
Vertex meets own cystic fibrosis record with next-gen treatment

Vertex meets own cystic fibrosis record with next-gen treatment
FIERCE BIOTECH
06 Feb 2024
Share Share
Vertex Announces EMA Validation for MAA Extension for KAFTRIO

Vertex Announces EMA Validation for MAA Extension for KAFTRIO
BUSINESSWIRE
24 Nov 2023
Share Share
EC Approves KAFTRIO® in Combination With Ivacaftor

EC Approves KAFTRIO® in Combination With Ivacaftor
BUSINESSWIRE
23 Nov 2023
Share Share
NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds

NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds
Fraiser Kansteiner FIERCE PHARMA
07 Nov 2023
Share Share
Vertex Receives CHMP Positive Opinion for KAFTRIO

Vertex Receives CHMP Positive Opinion for KAFTRIO
BUSINESSWIRE
15 Sep 2023
Share Share
European Commission Approves ORKAMBI for Cystic Fibrosis

European Commission Approves ORKAMBI for Cystic Fibrosis
BUSINESSWIRE
05 Jul 2023
Share Share
Vertex secures FDA clearance for infants’ cystic fibrosis therapy

Vertex secures FDA clearance for infants’ cystic fibrosis therapy
PHARMACEUTICAL TECHNOLOGY
05 May 2023
Share Share